Propanc Biopharma (PPCB) EBT (2010 - 2025)
Propanc Biopharma (PPCB) posted quarterly EBT of -$3.1 million for Q4 2025, down 618.62% year-over-year from $596077.3 in Q4 2024, and up 36.1% quarter-over-quarter from -$4.8 million in Q3 2025.
Propanc Biopharma (PPCB) EBT (2010 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported EBT for 16 consecutive years, with -$3.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, EBT fell 618.62% year-over-year to -$3.1 million; the TTM figure through Dec 2025 stood at -$66.1 million (down 3855.49% YoY), while the FY2025 annual figure was -$58.9 million, down 2922.23% from the prior year.
- EBT grew to -$3.1 million in Q4 2025 per PPCB's latest filing, from -$4.8 million in the prior quarter.
- Across five years, EBT topped out at -$350866.0 in Q3 2023 and bottomed at -$54.1 million in Q1 2025.
- Historically, EBT has averaged -$3.8 million across 5 years, with a median of -$665149.5 in 2022.
- Annual changes were most pronounced in 2021 — EBT jumped 79.71% — and 2025, when it slumped 10159.95%.
- Propanc Biopharma's EBT stood at -$855440.0 in 2021, then grew by 28.14% to -$614739.0 in 2022, then declined by 15.98% to -$713004.0 in 2023, then surged by 39.67% to -$430183.0 in 2024, then plunged by 618.62% to -$3.1 million in 2025.
- Business Quant data shows PPCB's EBT at -$3.1 million in Q4 2025, -$4.8 million in Q3 2025, and -$4.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | -3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.09 Mn |
| Sep 30, 2025 | -4.84 Mn |
| Jun 30, 2025 | -4.07 Mn |
| Mar 31, 2025 | -54.07 Mn |
| Dec 31, 2024 | -430,183.00 |
| Sep 30, 2024 | -354,310.00 |
| Jun 30, 2024 | -358,815.00 |
| Mar 31, 2024 | -526,975.00 |
| Dec 31, 2023 | -713,004.00 |
| Sep 30, 2023 | -350,866.00 |
| Jun 30, 2023 | -746,848.00 |
| Mar 31, 2023 | -811,525.00 |
| Dec 31, 2022 | -614,739.00 |
| Sep 30, 2022 | -617,295.00 |
| Jun 30, 2022 | -904,492.00 |
| Mar 31, 2022 | -462,474.00 |
| Dec 31, 2021 | -855,440.00 |
| Sep 30, 2021 | -490,658.00 |
| Jun 30, 2021 | -780,159.00 |
| Mar 31, 2021 | -530,015.00 |